Table 3 Association between pathological features and either/or co-expression of mesothelin and CA125
From: Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis
Parameter | Mesothelin Expression | CA125 Expression | Co-Expression of mesothelin and CA125 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Positive | Negative | p-value | Positive | Negative | p-value | Positive | Negative | p-value | |||||||
(n = 171) | (n = 314) | (n = 368) | (n = 117) | (n = 167) | (n = 318) | ||||||||||
Age | |||||||||||||||
  ≥ 60 | 99 | (58%) | 153 | (49%) | 0.053 | 188 | (51%) | 64 | (55%) | 0.52 | 97 | (58%) | 155 | (49%) | 0.055 |
  <  60 | 72 | (42%) | 161 | (51%) |  | 180 | (49%) | 53 | (45%) |  | 70 | (42%) | 163 | (51%) |  |
FIGO stage | |||||||||||||||
 I and II | 124 | (73%) | 242 | (77%) | 0.27 | 280 | (76%) | 86 | (74%) | 0.62 | 120 | (72%) | 246 | (77%) | 0.18 |
 III and IV | 47 | (27%) | 72 | (23%) |  | 88 | (24%) | 31 | (26%) |  | 47 | (28%) | 72 | (23%) |  |
Depth of myometrial invasion | |||||||||||||||
  ≥ 1/2 | 71 | (42%) | 99 | (32%) | 0.028 | 128 | (35%) | 42 | (36%) | 0.82 | 71 | (42%) | 99 | (31%) | 0.016 |
  < 1/2 | 100 | (58%) | 215 | (68%) |  | 240 | (65%) | 75 | (64%) |  | 96 | (58%) | 219 | (69%) |  |
Lymphovascular invasion | |||||||||||||||
 Yes | 85 | (50%) | 123 | (39%) | 0.027 | 156 | (42%) | 52 | (44%) | 0.74 | 84 | (50%) | 124 | (39%) | 0.02 |
 No | 86 | (50%) | 191 | (61%) |  | 212 | (58%) | 65 | (56%) |  | 83 | (50%) | 194 | (61%) |  |
Cervical invasion | |||||||||||||||
 Yes | 27 | (16%) | 66 | (21%) | 0.18 | 71 | (19%) | 22 | (19%) | 1.0 | 27 | (16%) | 66 | (21%) | 0.27 |
 No | 144 | (84%) | 248 | (79%) |  | 297 | (81%) | 95 | (81%) |  | 140 | (84%) | 252 | (79%) |  |
Ovarian metastasis | |||||||||||||||
 Yes | 14 | (8%) | 16 | (5%) | 0.23 | 24 | (7%) | 6 | (5%) | 0.66 | 14 | (8%) | 16 | (5%) | 0.16 |
 No | 157 | (92%) | 298 | (95%) |  | 344 | (93%) | 111 | (95%) |  | 153 | (92%) | 302 | (95%) |  |
Lymph node metastasis | |||||||||||||||
 Yes | 27 | (16%) | 38 | (12%) | 0.35 | 50 | (14%) | 15 | (13%) | 0.93 | 27 | (16%) | 38 | (12%) | 0.30 |
 No | 111 | (65%) | 223 | (71%) |  | 254 | (69%) | 80 | (68%) |  | 108 | (65%) | 226 | (71%) |  |
 Unevaluated | 33 | (19%) | 53 | (17%) |  | 64 | (17%) | 22 | (19%) |  | 32 | (19%) | 54 | (17%) |  |
Distant metastasis | |||||||||||||||
 Yes | 17 | (10%) | 22 | (7%) | 0.29 | 27 | (7%) | 12 | (10%) | 0.33 | 17 | (10%) | 22 | (7%) | 0.22 |
 No | 154 | (90%) | 292 | (93%) |  | 341 | (93%) | 105 | (90%) |  | 150 | (90%) | 296 | (93%) |  |
Peritoneal cytology | |||||||||||||||
 Yes | 37 | (22%) | 52 | (17%) | 0.17 | 71 | (19%) | 18 | (15%) | 0.41 | 37 | (22%) | 52 | (17%) | 0.17 |
 No | 134 | (78%) | 262 | (83%) |  | 297 | (81%) | 99 | (85%) |  | 130 | (78%) | 266 | (83%) |  |
Adjuvant therapy | |||||||||||||||
 Yes | 99 | (58%) | 170 | (54%) | 0.44 | 201 | (55%) | 68 | (58%) | 0.52 | 98 | (59%) | 171 | (54%) | 0.33 |
 No | 72 | (42%) | 144 | (46%) |  | 167 | (45%) | 49 | (42%) |  | 69 | (41%) | 147 | (46%) |  |